021 566 12 22 -
info@retina-uveitis.ch
021 566 12 22 -
info@retina-uveitis.ch2026:
Modelling flow characteristics of subretinal injections- implications in clinical practice. PLOS One
Choroidal abnormalities: the new hallmark ocular finding in Neurofibromatosis type 1 -
A novel diagnostic and prognostic biomarker in vitreoretinal lymphoma. Ocul Immunol Inflamm
Novel Treatment for Non-Infectious Uveitis with Superior Intraocular Pressure Safety Profile:
A Randomized Clinical Trial. Am J Ophthalmol
Intravitreal management of ocular lymphoma should use adjusted drug concentrations not fixed dosages.